Biogen | BIIB - Stammkapital





Stammkapital Veränderung Datum
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
ALKERMES USD 166.46M 855K 2026-03
Amgen USD 540M 1000K 2026-03
Bayer EUR 982.42M 0 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Gilead Sciences USD 1.24B 1000K 2026-03
Incyte USD 199.95M 1.49M 2026-03
Merck USD 2.47B 12.72M 2025-12
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.6M 500K 2026-03
Novartis USD 1.91B 60K 2026-03
Pfizer USD 5.7B 13M 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sanofi EUR 1.21B 8.25M 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
Teva Pharmaceutical Industries USD 1.16B 16.72M 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
United Therapeutics USD 42.16M 1.49M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03